Business
SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’ - Yahoo Finance
What the report says
Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.
Loading debate for this article…
Other publishers covering this story
No additional verified coverage is currently clustered with this report.

Report highlights role of generic drugmakers in expanding medicine access in AfricaThe Observer
BRICS 2026: New Delhi prepares for a summit that could reshape the Global SouthNile Post
Uganda Unveils Pearl Sweet Crude at APPEC 2026 as First Oil NearsNile Post
Fresh Dispute Erupts Over Wakiso Market Stall AllocationNile Post